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INTRODUCTION
Research examining the neuropsychological outcomes of whole
brain radiation therapy (RT) plus intrathecal (IT) chemotherapy for
acute lymphoblastic leukemia (ALL) has indicated declines in
nonverbal intelligence, math achievement, visual-motor integra-
tion, processing speed, attention, executive functioning, and
memory [1–6]. Two meta-analytic reviews of the neuropsycho-
logical outcomes of RT [1,7] documented significantly decreased
intellectual functioning in ALL survivors, as well as poorer
academic achievement, attention, information processing, execu-
tive functioning, psychomotor and visuospatial skills, and memory
compared to controls. Both meta-analytic reviews included children
who had received RT; however, the outcomes of chemotherapy-only
treatment for ALL have not been subjected to meta-analytic review.
Campbell and colleagues [7] noted that their meta-analysis could
not conclusively determine the impact of chemotherapy-only
treatment. Thus, it is now important to describe, using meta-
analytic techniques, the long-term neuropsychological sequelae of
chemotherapy-only for pediatric leukemia.
Research suggests that the underlying basis for neuropsycho-
logical deficits may be the impact of radiation on white matter
density, by which impaired myelinization affects nondominant
hemisphere functions and slowed cortical activity [8,9]. Although
treatment protocols were modified so that few ALL patients receive
RT, most ALL patients still receive IT chemotherapy (particularly
methotrexate [MTX]), often combined with intravenous or oral
chemotherapy, resulting in high doses of systemic and central
nervous system (CNS)-targeted chemotherapeutic agents during
critical brain development. It has been reported that IT MTX, even
without RT, may be linked to white matter changes, calcifications,
leukoencephalopathy, cortical atrophy, and seizures [10].
One review of neuropsychological outcomes of CNS chemo-
therapy concluded that two-thirds of studies indicated decreased
intellectual functioning in ALL survivors receiving chemotherapy
compared to controls [10]. Numerous empirical studies of neuro-
psychological outcomes in ALL survivors have indicated deficits in
performance IQ (PIQ) [11–14], academic achievement [13,15,16],
and specific cognitive skills including processing speed, attention,
visual-spatial skills, fine motor skills, and nonverbal memory
[12,17–20]. Some studies, however, report only slight or no
impairment [21,22]. To reconcile these mixed findings, and given
evidence of neuropsychological dysfunction associated with CNS
treatment for ALL [10], it is critical to synthesize available data
using effect size statistics to estimate the impact of chemotherapy on
intellectual, neuropsychological, and academic outcomes.
METHOD
Article Identification
We conducted literature searches using MEDLINE and PsycInfo
databases and reference sections of relevant articles; additional
details of search terms and inclusion/exclusion criteria can be found
in the Supplementary materials. Following identification of relevant
articles, each article was examined in detail by the authors to
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determine that they included participants who had completed
chemotherapy-only treatment for pediatric ALL and a comparison
group that did not receive CNS treatment. Articles had to be in
English and include original empirical data sufficient to calculate
effect sizes (i.e., means, standard deviations, and sample sizes for
ALL and control groups). From the 160 articles, studies were
excluded due to sample characteristics (i.e., did not examine a
homogeneous ALL survivor sample or did not have an eligible
comparison group; 40%), were published prior to 1990 (to focus on
recent treatment protocols that administered CNS chemotherapy
only; 25%), did not report eligible neuropsychological data (11%),
or did not report any empirical data (9%). Of the 21 remaining
articles, eight were excluded due to unusable data (e.g., did not
report all necessary data; measures were not comparable to
measures in any other study).
For 13 articles meeting inclusion criteria [11–14,16–18,20–
25], the following variables were abstracted: sample size, gender,
mean age, mean age at diagnosis, ethnicity, SES, medical diagnoses,
treatment modalities, time since diagnosis, and means and standard
deviations for cognitive or academic outcomes. A neuropsycho-
logist verified that study measures were established neuropsycho-
logical measures (i.e., if cited in the Compendium of
Neuropsychological Tests [26]) versus an investigator’s own
measure and classified variables into constructs. See Table I for a
summary of the 13 articles and sample demographics.
Effect Size Calculations
Effect sizes were calculated using ZumaStat software [27] to
compare ALL and comparison groups on outcome measures.
Differences between control group means and ALL group means
were divided by the pooled group standard deviations, yielding a
Cohen’s d for each construct [28]. Random effects models, weighted
least squares methods, were employed for primary analyses [29]. A
positive effect size indicated better performance in the control
group. Cohen’s classification was used to interpret effect sizes,
where a mean effect size of M¼ 0.20 is considered a small effect,
M¼ 0.50 is medium, and M¼ 0.80 is large.
Tests of Homogeneity (QT)
The test of QT indicates the internal consistency of study
outcome groupings. A significant QT indicates that variability in the
sample is greater than expected from sampling error alone and the
data should be examined for moderating factors [30]. When Q
statistics were significant, effect sizes were re-calculated excluding
studies that used test normative data for their comparison group, as
those samples were significantly larger than recruited control
groups. If the QT was still significant, effect sizes were re-calculated
excluding studies that used translations of tests, due to the potential
for a translated test not to be comparable to the original version,
thereby creating increased variance. Test norms and translations
were selected for removal because they potentially decrease
neuropsychological assessment reliability across studies.
Gender Analyses
Based on literature indicating increased neuropsychological
sequelae for girls with ALL [31], post hoc analyses of variance
(ANOVAs) were calculated if effect sizes were heterogeneous based
on the Q statistic. Two studies were identified that reported sufficient
data separated by gender.
RESULTS
The overall ALL sample contained a mean of 27 participants per
study (M age¼ 5.3 years at diagnosis; M time since
treatment¼ 4.7 years; M age¼ 11.1 years at assessment). Gender
breakdown was 13.6 females and 14.4 males per study. Comparison
groups (excluding studies that used test norm groups for comparison
groups) had a mean of 26 participants per study (M age¼ 12.0 years
at assessment). Gender breakdown of comparison groups was
13.6 females and 14.7 males per study. Nine studies reported
information regarding participant ethnicities, which was predom-
inantly Caucasian. Specific chemotherapy protocols were described
in nine studies, and all included IT chemotherapy; seven of the nine
specified that patients received triple IT (TIT) chemotherapy (MTX,
cytosine arabinoside, and hydrocortisone). All studies were cross-
sectional.
Mean effect sizes were calculated for full scale intelligence
(FSIQ), verbal IQ (VIQ), PIQ, math achievement, reading achieve-
ment, freedom from distractibility index, perceptual organization
index, coding, digit span, finger tapping, Purdue pegboard (both
hands), Purdue pegboard (preferred hand), trails B, and verbal
memory. Table II presents weighted mean effect sizes, confidence
intervals, and Q statistics for all constructs. With one exception
(finger tapping), significant group differences indicated poorer
functioning in the ALL group.
Intelligence
Mean effect sizes for FSIQ were significantly different from zero
(M¼ 0.55, 95% CI¼ .27–0.83, n¼ 10), indicating that children
with ALL had significantly lower FSIQ scores relative to control
groups. The Q statistic for QT was significant (QT¼ 22.85,
P< 0.01). Therefore, mean effect sizes were recalculated by
eliminating three studies that utilized test norms as a comparison
group. The resulting effect size was larger (M¼ 0.76, 95%
CI¼ 0.26–1.26, n¼ 7), but the Q still indicated heterogeneity
(QT¼ 22, P< 0.01). Next, the three studies utilizing foreign
translations of the measure were excluded; the recalculated mean
effect size was still significantly different from zero (M¼ 0.76, 95%
CI¼ 0.42–1.12, n¼ 7), and the Q was not significant. Results
suggest that ALL survivors demonstrated significantly lower IQ
scores than controls.
Similar results were found for index scores of the Wechsler
intelligence measures [32–35]. Children with ALL had signifi-
cantly lower VIQ and PIQ scores, with a medium mean effect size
significantly different from zero. The Q statistic was significant for
VIQ and PIQ and remained significant excluding norms. The
freedom from distractibility index and perceptual organization
index scores were significantly different from zero (Q statistics not
significant), indicating lower scores in the ALL group. The verbal
comprehension index did not significantly differ between groups
(n¼ 2).
Subtest-level findings were inconsistent. Effect sizes were
significantly different from zero for digit span and coding but not
for arithmetic, block design, similarities, or vocabulary. Q statistics
were significant for arithmetic, block design, and coding; when
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arithmetic and coding were re-analyzed excluding translations, the
recalculated arithmetic mean effect size was not significant, whereas
the coding recalculated mean effect size was significant.
Academic Achievement
Effect sizes were significantly different from zero for math
achievement and reading achievement. Results suggest that ALL
survivors demonstrated significantly lower academic achievement
than comparison groups on both achievement domains.
Neuropsychological Constructs
Results were inconsistent for measures of visual-motor integra-
tion, fine motor skills, and reaction time. Effect sizes were
significantly different from zero on the Purdue pegboard task for
both hands and preferred hand but not for Assembly. Q statistics
were not significant. Effect sizes for VMI were not significant.
Effect sizes were significantly different from zero for the finger
tapping test, but effect sizes were negative, indicating that the ALL
group scored higher on this test than the comparison groups.
Children with ALL performed significantly worse on Trails B (a
measure of executive functioning) but not Trails A (a measure of fine
motor tracking). Verbal fluency comparison was not significant. The
effect size for verbal memory was significantly different from zero,
indicating that children with ALL performed more poorly than
controls. Visual memory effect sizes were not significant.
Gender Comparisons
Post hoc ANOVAs on IQ constructs were conducted to explore
potential gender differences [31]. Mean effect sizes were signifi-
cantly different from zero for FSIQ (M¼0.57, 95% CI¼0.86–
0.28, n¼ 2), PIQ (M¼0.49, 95% CI¼0.78–0.19, n¼ 2),
and VIQ (M¼0.51, 95% CI¼0.80–0.21, n¼ 2), indicating
that girls performed worse than boys.
DISCUSSION
These findings present empirical support, using effect size
statistics, for a pattern of neuropsychological sequelae of modern
chemotherapy-only treatment protocols. These effect size data
support research documenting neuropsychological late effects of
childhood cancer, particularly given recent reports of no impairment
or only mild impairment on select outcome measures following
chemotherapy [22]. Results suggest that intellectual functioning
does appear to be affected in ALL patients, even without RT,
particularly in the areas of perceptual reasoning skills, working
memory, and processing speed. Verbal subtests, however, were not
significantly different between the groups, suggesting that select
verbal skills may be spared in ALL survivors. This pattern of
strengths and weaknesses is consistent with previously reviewed
evidence [10], but this meta-analytic review provides synthesis of
effect sizes from multiple studies supporting this pattern of strengths
and weaknesses in ALL survivors.
Findings indicated that ALL survivors exhibit difficulty attaining
academic progress in both math and reading. Although previous
research has focused on math achievement [16], these data suggest
that reading achievement also may be affected. Neuropsychological
findings were mixed, with some evidence of fine motor, executive
function, and verbal memory weaknesses in ALL survivors. These
results, however, were based on very small samples and therefore,
should be interpreted very cautiously. Post hoc analyses examining
gender differences on intelligence tests also were based on small
samples, so these findings must be interpreted with extreme caution.
Nonetheless, our finding was consistent with reports that girls may
Pediatr Blood Cancer DOI 10.1002/pbc


















Kaemingk et al. [16] 15 5.44 4.4 12.62 40 a, b 15 11.97 40
Schatz et al. [20] 8 7 6.7 13.9 75 a, b 24 17.4 58
Brown et al. [25] 11 NR 1 7.55 64 a 12 9.02 50
Hill et al. [17] 10 1–5 years 3 10.3 NR a, b 10 10.1 NR
Lesnick et al. [18] 10 1–5 years 3 6.9–13.5 60 a, b 10 6.0–13.0 60
Raymond-Speden et al. [13] 21 4.1 4.9 9.4 43 b 21 10.6 48
Giralt et al. [12] 29 5.48 3 11.37 48 a, c 46 11.46 37
von der Weid et al. [14] 132 4.8* 2 14.7* 50 c 100 15.8* 46
Rodgers et al. [21] 17 4 5 9.72 35 a 17 11.5 59
Kingma et al. [23] 17 3.5* 5 9.3* 41 d 225 NR NR
Kingma et al. [22] 20 3.4* NR 10.3* 45 d 225 NR NR
Schatz et al. [24] 9 6.9 6.9 13.9 78 a, b 9 14.3 78
Brown et al. [11] 20–43 4.3 3.8 11 43 d ** NR NR
ALL, acute lymphoblastic leukemia; NR, not reported. Control group types: a, healthy, family member (e.g., sibling); b, healthy, non-family (e.g.,
friend, neighbor, classmate); c, cancer patient, non-CNS tumor; d, test normative sample; *reported median versus mean for age variables; therefore,
these studies were excluded from mean age calculations of overall sample; **control N varied depending on test used: Wechsler Intelligence Scale
for Children (WISC) normative sample¼ 2,200; Woodcock–Johnson (WJ) normative sample¼ 3,245; Beery Test of Visual-Motor Integration
(VMI) normative sample¼ 2,734.
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be at greater risk for neuropsychological late effects than boys [31],
warranting further investigation into gender differences in neuro-
psychological development.
The limitations of the meta-analysis reflect the state of the
literature, particularly the limited number of studies that could be
included due to methodological variability. We could not perform
post hoc ANOVAs on potential risk factors of age at diagnosis
and time since diagnosis, as few studies presented data separated
into groups by age at diagnosis or time since diagnosis. Further,
several studies were excluded due to the use of translated or newly
developed measures that were not comparable to established
neuropsychological measures. Other studies used heterogeneous
samples such as a cancer sample that included another leukemia
subtype or lymphoma. We focused on a homogeneous ALL sample,
despite the loss of usable data, to facilitate more precise under-
standing of neuropsychological sequelae of a specific treatment
component for ALL. A meta-analysis also can be limited by the
impact of publication bias, which may attenuate the strength of
effects found. It was not possible to illustrate publication bias for
visual examination, however, as the number of studies was far too
small for accurate interpretation [30].
These findings have bearing on future research and clinical
practice in the management of neuropsychological sequelae of
pediatric ALL. Treatment intensity may be an important moderator
of outcomes, as multiple IT agents (e.g., TIT chemotherapy) may
impact neuropsychological sequelae. It has been proposed that IT
cytosine arabinoside may actually exacerbate the neurotoxicity of
IT MTX [12]. Because few studies reported treatment protocol
details, we could not examine treatment intensity as a moderator.
Research also should examine other treatment modalities that have
been implicated in neuropsychological dysfunction, such as
corticosteroids (e.g., dexamethasone) [36]. Finally, interventions
need to be studied, such as cognitive remediation [37], psychosti-
mulant medication [38], and intensive tutoring [39].
Future research also must use carefully matched comparison
groups, as studies may be of limited generalizability if they use
Pediatr Blood Cancer DOI 10.1002/pbc
TABLE II. Weighted Mean Effect Sizes; 95% Confidence Intervals; and Q Statistics for
Neuropsychological Constructs
Measure/construct N of studies
Weighted
M ES 95% CI Q
General intelligence 10 0.55** 0.27–0.83 22.85**
Excluding normative data{ 7 0.76** 0.26–1.26 22**
Excluding translations{ 7 0.76** 0.42–1.12 10.72
Verbal IQ 6 0.46** 0.11–0.81 18.06**
Excluding normative data 3 0.86 0.09–1.81 14.90**
Excluding translations 3 0.87 0.06–1.80 13.59**
Performance IQ 6 0.42* 0.03–0.81 23.58**
Excluding normative data 3 0.64 0.27–1.55 14.30**
Excluding translations 3 0.73* 0.14–1.32 5.78
Freedom from distractibility index 2 0.54** 0.25–0.83 0.13
Perceptual organization index 2 0.70** 0.40–0.99 0.96
Verbal comprehension index 2 0.48 0.38–1.33 5.73*
Arithmetic (Wechsler subtest) 3 0.40 0.19–0.99 6.75*
Excluding translations 2 0.66 0.26–1.58 3.23
Block design (Wechsler subtest) 2 0.27 0.34–0.88 4.07*
Coding (Wechsler subtest) 4 0.48 0.02–0.98 9.73*
Excluding translations 3 0.70** 0.27–1.12 2.28
Digit span (Wechsler subtest) 6 0.28* 0.04–0.52 7.35
Similarities (Wechsler subtest) 2 0.34 0.14–0.81 2.56
Vocabulary (Wechsler subtest) 2 0.27 0.16–0.70 2.19
Math achievement 5 0.61** 0.20–1.03 7.88
Reading achievement 5 0.65* 0.03–1.27 17.54**
Excluding normative data 4 0.87** 0.48–1.26 2.31
VMI 4 0.37 0.19–0.93 13.95**
Finger tapping (preferred hand) 2 0.35* 0.68–0.01 0.94
Purdue pegboard (assembly) 2 0.11 0.45–0.22 0.09
Purdue pegboard (both hands) 2 0.38* 0.04–0.71 0.04
Purdue pegboard (preferred hand) 3 0.39* 0.08–0.69 1.94
Verbal fluency 2 0.41 0.06–0.88 0.86
Trails A 3 0.32 0.24–0.87 4.65
Trails B 3 0.70** 0.18–1.23 3.97
Verbal memory 2 1.16** 0.54–1.79 1.06
Visual memory 2 1.03 0.64–2.70 6.84**
ES, effect size; CI, confidence interval; IQ, intelligence quotient; VMI, Beery test of visual-motor
integration; *P< 0.05; **P< 0.01; {when the Q statistic indicated significant heterogeneity, analyses were
re-run excluding either: (a) studies that used normative data as their comparison group versus a recruited
control sample, or (b) studies that used translated versions of tests originally created in English, in order to
reduce the potential for heterogeneity whenever possible. All data that could be calculated are presented.
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normative data as a comparison group, newly created measures, or
IQ tests only [2,10]. It is important to develop a standardized battery
within each culture to obtain the best estimate of neuropsycho-
logical sequelae in a culturally fair manner. Finally, studies from
other cultures may reflect a different medical treatment protocol or
some unique aspect of supportive intervention (e.g., more intense
tutoring) during cancer treatment. Future studies may benefit from
examining supportive academic interventions in more detail as a
potential moderator.
These findings inform clinical care, as individualized neuro-
psychological monitoring and academic intervention (e.g., special
education, classroom accommodations) may enhance functional
outcomes for ALL survivors including graduation and job attain-
ment rates and long-term adaptive skills to transition to adulthood. A
standardized neuropsychological test battery is critical; one has
been proposed [40], although widespread implementation (partic-
ularly internationally) may be hindered by obstacles such as variable
institutional commitment to neuropsychological assessment and
insurance reimbursement issues. Finally, baseline testing of all
young ALL patients is needed to track neuropsychological and
academic skills over time to facilitate early intervention and prevent
academic failure.
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